GP VI–Mediated Platelet Activation and Procoagulant Activity Aggravate Inflammation and Aortic Wall Remodeling in Abdominal Aortic Aneurysm
Arteriosclerosis, Thrombosis, and Vascular Biology
Abstract
BACKGROUND:
Platelets play an important role in cardiovascular and cerebrovascular diseases. Abdominal aortic aneurysm (AAA) is a highly lethal, atherosclerosis-related disease with characteristic features of progressive dilatation of the abdominal aorta and degradation of the vessel wall, accompanied by chronic inflammation. Platelet activation and procoagulant activity play a decisive role in the AAA pathology as they might trigger AAA development in both mice and humans.
METHODS:
The present study investigated the impact of the major platelet collagen receptor GP (platelet glycoprotein) VI in pathophysiological processes underlying AAA initiation and progression. For experimental AAA induction in mice, PPE (porcine pancreatic elastase) and the external PPE model were used.
RESULTS:
Genetic deletion of GP VI offered protection of mice against aortic diameter expansion in experimental AAA. Mechanistically, GP VI deficiency resulted in decreased inflammation with reduced infiltration of neutrophils and platelets into the aortic wall. Furthermore, remodeling of the aortic wall was improved in the absence of GP VI, as indicated by reduced MMP (matrix metalloproteinase)-2/9 and OPN (osteopontin) plasma levels and an enhanced α-SMA (α-smooth muscle actin) content within the aortic wall, accompanied by reduced cell apoptosis. Consequently, an elevation in intima/media thickness and elastin content was observed in GP VI–deficient PPE mice, resulting in a significantly reduced aortic diameter expansion and reduced aneurysm incidence. In patients with AAA, enhanced plasma levels of soluble GP VI and fibrin, as well as fibrin accumulation within the intraluminal thrombus might serve as new biomarkers to detect AAA early. Moreover, we hypothesize that GP VI might play a role in procoagulant activity and thrombus stabilization via binding to fibrin.
CONCLUSIONS:
In conclusion, our results emphasize the potential need for a GP VI–targeted antiplatelet therapy to reduce AAA initiation and progression, as well as to protect patients with AAA from aortic rupture.
Graphical Abstract
Get full access to this article
View all available purchase options and get full access to this article.
Supplemental Material
File (atvb_atvb-2023-320615_supp1.pdf)
- Download
- 3.30 MB
REFERENCES
1.
Firnhaber JM, Powell CS. Arterial atherosclerosis: vascular surgery interventions. Am Fam Physician. 2022;105:65–72.
2.
Song P, He Y, Adeloye D, Zhu Y, Ye X, Yi Q, Rahimi K, Rudan I; Global Health Epidemiology Research Group (GHERG). The global and regional prevalence of abdominal aortic aneurysms: a systematic review and modelling analysis. Ann Surg. 2022;277:912–919. doi: 10.1097/SLA.0000000000005716
3.
Cameron SJ, Russell HM, Owens AP. Antithrombotic therapy in abdominal aortic aneurysm: beneficial or detrimental? Blood. 2018;132:2619–2628. doi: 10.1182/blood-2017-08-743237
4.
Golledge J, Morris DR, Pinchbeck J, Rowbotham S, Jenkins J, Bourke M, Bourke B, Norman PE, Jones R, Moxon JV. Editor’s choice - metformin prescription is associated with a reduction in the combined incidence of surgical repair and rupture related mortality in patients with abdominal aortic aneurysm. Eur J Vasc Endovasc Surg. 2019;57:94–101. doi: 10.1016/j.ejvs.2018.07.035
5.
Karrowni W, Dughman S, Hajj GP, Miller FJ. Statin therapy reduces growth of abdominal aortic aneurysms. J Investig Med. 2011;59:1239–1243. doi: 10.2130/JIM.0b013e31823548e8
6.
Kunath A, Unosson J, Friederich-Persson M, Bjarnegård N, Becirovic-Agic M, Björck M, Mani K, Wanhainen A, Wågsäter D. Inhibition of angiotensin-induced aortic aneurysm by metformin in apolipoprotein E-deficient mice. JVS Vasc Sci. 2021;2:33–42. doi: 10.1016/j.jvssci.2020.11.031
7.
Sutton SS, Magagnoli J, Cummings TH, Hardin JW. Association between metformin and abdominal aortic aneurysm in diabetic and non-diabetic US veterans. J Investig Med. 2020;68:1015–1018. doi: 10.1136/jim-2019-001177
8.
Sakalihasan N, Limet R, Defawe OD. Abdominal aortic aneurysm. Lancet. 2005;365:1577–1589. doi: 10.1016/S0140-6736(05)66459-8
9.
Shimizu K, Mitchell RN, Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2006;26:987–994. doi: 10.1161/01.ATV.0000214999.12921.4f
10.
Gawaz M, Vogel S. Platelets in tissue repair: control of apoptosis and interactions with regenerative cells. Blood. 2013;122:2550–2554. doi: 10.1182/blood-2013-05-468694
11.
Lindholt JS, Björck M, Michel JB. Anti-platelet treatment of middle-sized abdominal aortic aneurysms. Curr Vasc Pharmacol. 2013;11:305–313. doi: 10.2174/1570161111311030005
12.
Busch A, Bleichert S, Ibrahim N, Wortmann M, Eckstein HH, Brostjan C, Wagenhäuser MU, Goergen CJ, Maegdefessel L. Translating mouse models of abdominal aortic aneurysm to the translational needs of vascular surgery. JVSVasc Sci. 2021;2:219–234. doi: 10.1016/j.jvssci.2021.01.002
13.
Dai J, Louedec L, Philippe M, Michel JB, Houard X. Effect of blocking platelet activation with AZD6140 on development of abdominal aortic aneurysm in a rat aneurysmal model. J Vasc Surg. 2009;49:719–727. doi: 10.1016/j.jvs.2008.09.057
14.
Hannawa KK, Cho BS, Sinha I, Roelofs KJ, Myers DD, Wakefield TJ, Stanley JC, Henke PK, Upchurch GR. Attenuation of experimental aortic aneurysm formation in P-selectin knockout mice. Ann NY Acad Sci. 2006;1085:353–359. doi: 10.1196/annals.1383.014
15.
Metz LM, Feige T, de Biasi L, Ehrenberg A, Mulorz J, Toska LM, Reusswig F, Quast C, Gerdes N, Kelm M, et al. Platelet pannexin-1 channels modulate neutrophil activation and migration but not the progression of abdominal aortic aneurysm. Front Mol Biosci. 2023;10:1111108. doi: 10.3389/fmolb.2023.1111108
16.
Morrell CN, Mix D, Aggarwal A, Bhandari R, Godwin M, Owens P, Lyden SP, Doyle A, Krauel K, Rondina MT, et al. Platelet olfactory receptor activation limits platelet reactivity and growth of aortic aneurysms. J Clin Invest. 2022;132:e152373. doi: 10.1172/JCI152373
17.
Owens AP, Edwards TL, Antoniak S, Geddings JE, Jahangir E, Wei WQ, Denny JC, Boulaftali Y, Bergmeier W, Daugherty A, et al. Platelet inhibitors reduce rupture in a mouse model of established abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 2015;35:2032–2041. doi: 10.1161/ATVBAHA.115.305537
18.
Touat Z, Ollivier V, Dai J, Huisse MG, Bezeaud A, Sebbag U, Palombi T, Rossignol P, Meilhac O, Guillin MC, et al. Renewal of mural thrombus releases plasma markers and is involved in aortic abdominal aneurysm evolution. Am J Pathol. 2006;168:1022–1030. doi: 10.2353/ajpath.2006.050868
19.
Wagenhauser MU, Mulorz J, Krott KJ, Bosbach A, Feige T, Rhee YH, Chatterjee M, Petzold N, Böddeker C, Ibing W, et al. Crosstalk of platelets with macrophages and fibroblasts aggravates inflammation, aortic wall stiffening, and osteopontin release in abdominal aortic aneurysm. Cardiovasc Res. 2024;120:417–432. doi: 10.1093/cvr/cvad168
20.
Gröschel K, Uphaus T, Loftus I, Poppert H, Diener HC, Zobel J, Münch G. Revacept, an inhibitor of platelet adhesion in symptomatic carotid artery stenosis: design and rationale of a randomized phase II clinical trial. TH Open. 2020;4:e393–e399. doi: 10.1055/s-0040-1721078
21.
Mayer K, Hein-Rothweiler R, Schüpke S, Janisch M, Bernlochner I, Ndrepepa G, Sibbing D, Gori T, Borst O, Holdenrieder S, et al. Efficacy and safety of revacept, a novel lesion-directed competitive antagonist to platelet glycoprotein VI, in patients undergoing elective percutaneous coronary intervention for stable ischemic heart disease: the randomized, double-blind, placebo-controlled ISAR-PLASTER phase 2 trial. JAMA Cardiol. 2021;6:753–761. doi: 10.1001/jamacardio.2021.0475
22.
Pachel C, Mathes D, Arias-Loza AP, Heitzmann W, Nordbeck P, Deppermann C, Lorenz V, Hofmann U, Nieswandt B, Frantz S. Inhibition of platelet GPVI protects against myocardial ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol. 2016;36:629–635. doi: 10.1161/ATVBAHA.115.305873
23.
Rout A, Tantry US, Novakovic M, Sukhi A, Gurbel PA. Targeted pharmacotherapy for ischemia reperfusion injury in acute myocardial infarction. Expert Opin Pharmacother. 2020;21:1851–1865. doi: 10.1080/14656566.2020.1787987
24.
Schönberger T, Ziegler M, Borst O, Konrad I, Nieswandt B, Massberg S, Ochmann C, Jürgens T, Seizer P, Langer H, et al. The dimeric platelet collagen receptor GPVI-Fc reduces platelet adhesion to activated endothelium and preserves myocardial function after transient ischemia in mice. Am J Physiol Cell Physiol. 2012;303:C757–C766. doi: 10.1152/ajpcell.00060.2012
25.
Wichaiyo S, Parichatikanond W, Rattanavipanon W. Glenzocimab: a GPVI (glycoprotein VI)-targeted potential antiplatelet agent for the treatment of acute ischemic stroke. Stroke. 2022;53:3506–3513. doi: 10.1161/STROKEAHA.122.039790
26.
Lu G, Su G, Davis JP, Schaheen B, Downs E, Roy RJ, Ailawadi G, Upchurch GR. A novel chronic advanced stage abdominal aortic aneurysm murine model. J Vasc Surg. 2017;66:232–242.e4. doi: 10.1016/j.jvs.2016.07.105
27.
Cebo M, Dittrich K, Fu X, Manke MC, Emschermann F, Rheinlaender J, von Eysmondt H, Ferreirós N, Sudman J, Witte A, et al. Platelet ACKR3/CXCR7 favors antiplatelet lipids over an atherothrombotic lipidome and regulates thromboinflammation. Blood. 2022;139:1722–1742. doi: 10.1182/blood.2021013097
28.
Jarre A, Gowert NS, Donner L, Münzer P, Klier M, Borst O, Schaller M, Lang F, Korth C, Elvers M. Pre-activated blood platelets and a pro-thrombotic phenotype in APP23 mice modeling Alzheimer’s disease. Cell Signal. 2014;26:2040–2050. doi: 10.1016/j.cellsig.2014.05.019
29.
Reusswig F, Polzin A, Klier M, Dille MA, Ayhan A, Benkhoff M, Lersch C, Prinz A, Gorressen S, Fischer JW, et al. Only acute but not chronic thrombocytopenia protects mice against left ventricular dysfunction after acute myocardial infarction. Cells. 2022;11:3500. doi: 10.3390/cells11213500
30.
Reusswig F, Dille M, Kruger E, Ortscheid J, Feige T, Gorressen S, Fischer JW, Elvers M. Platelets modulate cardiac remodeling via the collagen receptor GPVI after acute myocardial infarction. Front Immunol. 2023;14:1275788. doi: 10.3389/fimmu.2023.1275788
31.
Swamydas M, Luo Y, Dorf ME, Lionakis MS. Isolation of mouse neutrophils. Curr Protoc Immunol. 2015;110:3.20.1–3.20.15. doi: 10.1002/0471142735.im0320s110
32.
Donner L, Toska LM, Kruger I, Groniger S, Barroso R, Burleigh A, Mezzano D, Pfeiler S, Kelm M, Gerdes N, et al. The collagen receptor glycoprotein VI promotes platelet-mediated aggregation of beta-amyloid. Sci Signal. 2020;13:eaba9872. doi: 10.1126/scisignal.aba9872
33.
Bigalke B, Stellos K, Geisler T, Kremmer E, Seizer P, May AE, Lindemann S, Melms A, Luft A, Gawaz M. Expression of platelet glycoprotein VI is associated with transient ischemic attack and stroke. Eur J Neurol. 2010;17:111–117. doi: 10.1111/j.1468-1331.2009.02754.x
34.
Papapanagiotou A, Daskalakis G, Siasos G, Gargalionis A, Papavassiliou AG. The role of platelets in cardiovascular disease: molecular mechanisms. Curr Pharm Des. 2016;22:4493–4505. doi: 10.2174/1381612822666160607064118
35.
Hughan SC, Hughes CE, McCarty OJT, Schweighoffer E, Soultanova I, Ware J, Tybulewicz VLJ, Watson SP. GPVI potentiation of platelet activation by thrombin and adhesion molecules independent of Src kinases and Syk. Arterioscler Thromb Vasc Biol. 2007;27:422–429. doi: 10.1161/01.ATV.0000252826.96134.21
36.
Mammadova-Bach E, Ollivier V, Loyau S, Schaff M, Dumont B, Favier R, Freyburger G, Latger-Cannard V, Nieswandt B, Gachet C, et al. Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation. Blood. 2015;126:683–691. doi: 10.1182/blood-2015-02-629717
37.
Leo L, Di Paola J, Judd BA, Koretzky GA, Lentz SR. Role of the adapter protein SLP-76 in GPVI-dependent platelet procoagulant responses to collagen. Blood. 2002;100:2839–2844. doi: 10.1182/blood-2002-04-1234
38.
Sundermann AC, Saum K, Conrad KA, Russell HM, Edwards TL, Mani K, Björck M, Wanhainen A, Owens AP. Prognostic value of D-dimer and markers of coagulation for stratification of abdominal aortic aneurysm growth. Blood Adv. 2018;2:3088–3096. doi: 10.1182/bloodadvances.2017013359
39.
Wallinder J, Bergqvist D, Henriksson AE. Haemostatic markers in patients with abdominal aortic aneurysm and the impact of aneurysm size. Thromb Res. 2009;124:423–426. doi: 10.1016/j.thromres.2009.01.016
40.
Liu O, Jia L, Liu X, Wang Y, Wang X, Qin Y, Du J, Zhang H. Clopidogrel, a platelet P2Y12 receptor inhibitor, reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. PLoS One. 2012;7:e51707. doi: 10.1371/journal.pone.0051707
41.
Burkard P, Schonhart C, Vogtle T, Kohler D, Tang L, Johnson D, Hemmen K, Heinze KG, Zarbock A, Hermanns HM, et al. A key role for platelet GPVI in neutrophil recruitment, migration, and NETosis in the early stages of acute lung injury. Blood. 2023;142:1463–1477. doi: 10.1182/blood.2023019940
42.
Denorme F, Manne BK, Portier I, Eustes AS, Kosaka Y, Kile BT, Rondina MT, Campbell RA. Platelet necrosis mediates ischemic stroke outcome in mice. Blood. 2020;135:429–440. doi: 10.1182/blood.2019002124
43.
Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, Weinblatt ME, Massarotti EM, Remold-O’Donnell E, Farndale RW, Ware J, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science. 2010;327:580–583. doi: 10.1126/science.1181928
44.
Claushuis TAM, de Vos AF, Nieswandt B, Boon L, Roelofs J, de Boer OJ, van ’t Veer C, van der Poll T. Platelet glycoprotein VI aids in local immunity during pneumonia-derived sepsis caused by gram-negative bacteria. Blood. 2018;131:864–876. doi: 10.1182/blood-2017-06-788067
45.
Pierre S, Linke B, Suo J, Tarighi N, Del Turco D, Thomas D, Ferreiros N, Stegner D, Frölich S, Sisignano M, et al. GPVI and thromboxane receptor on platelets promote proinflammatory macrophage phenotypes during cutaneous inflammation. J Invest Dermatol. 2017;137:686–695. doi: 10.1016/j.jid.2016.09.036
46.
Devi S, Kuligowski MP, Kwan RY, Westein E, Jackson SP, Kitching AR, Hickey MJ. Platelet recruitment to the inflamed glomerulus occurs via an alphaIIbbeta3/GPVI-dependent pathway. Am J Pathol. 2010;177:1131–1142. doi: 10.2353/ajpath.2010.091143
47.
Bigalke B, Elvers M, Schönberger T, Gawaz M. Platelet and soluble glycoprotein VI - novel applications in diagnosis and therapy. Curr Drug Targets. 2011;12:1821–1830. doi: 10.2174/138945011797635867
48.
Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation. 2007;115:2323–2330. doi: 10.1161/CIRCULATIONAHA.107.691279
49.
Meijer CA, Stijnen T, Wasser MN, Hamming JF, van Bockel JH, Lindeman JH; Pharmaceutical Aneurysm Stabilisation Trial Study Group. Doxycycline for stabilization of abdominal aortic aneurysms: a randomized trial. Ann Intern Med. 2013;159:815–823. doi: 10.7326/0003-4819-159-12-201312170-00007
50.
Sillesen H, Eldrup N, Hultgren R, Lindeman J, Bredahl K, Thompson M, Wanhainen A, Wingren U, Swedenborg J; AORTA Trial Investigators. Randomized clinical trial of mast cell inhibition in patients with a medium-sized abdominal aortic aneurysm. Br J Surg. 2015;102:894–901. doi: 10.1002/bjs.9824
51.
Wanhainen A, Mani K, Kullberg J, Svensjö S, Bersztel A, Karlsson L, Holst J, Gottsäter A, Linné A, Gillgren P, et al. The effect of ticagrelor on growth of small abdominal aortic aneurysms-a randomized controlled trial. Cardiovasc Res. 2020;116:450–456. doi: 10.1093/cvr/cvz133
52.
Balceniuk MD, Trakimas LE, Aghaie C, Mix D, Rasheed K, Ellis J, Glocker R, Doyle A, Stoner MC. Aspirin use is associated with decreased radiologically-determined thrombus sac volume in abdominal aortic aneurysms. Vascular. 2018;26:440–444. doi: 10.1177/1708538118762214
53.
Wang YD, Liu ZJ, Ren J, Xiang MX. Pharmacological therapy of abdominal aortic aneurysm: an update. Curr Vasc Pharmacol. 2018;16:114–124. doi: 10.2174/1570161115666170413145705
54.
Goebel S, Li Z, Vogelmann J, Holthoff HP, Degen H, Hermann DM, Gawaz M, Ungerer M, Münch G. The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke. PLoS One. 2013;8:e66960. doi: 10.1371/journal.pone.0066960
55.
Voors-Pette C, Lebozec K, Dogterom P, Jullien L, Billiald P, Ferlan P, Renaud L, Favre-Bulle O, Avenard G, Machacek M, et al. Safety and tolerability, pharmacokinetics, and pharmacodynamics of ACT017, an antiplatelet GPVI (glycoprotein VI) Fab. Arterioscler Thromb Vasc Biol. 2019;39:956–964. doi: 10.1161/ATVBAHA.118.312314
56.
Ungerer M, Rosport K, Bultmann A, Piechatzek R, Uhland K, Schlieper P, Gawaz M, Münch G. Novel antiplatelet drug revacept (dimeric glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation. 2011;123:1891–1899. doi: 10.1161/CIRCULATIONAHA.110.980623
57.
Lebozec K, Jandrot-Perrus M, Avenard G, Favre-Bulle O, Billiald P. Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks. mAbs. 2017;9:945–958. doi: 10.1080/19420862.2017.1336592
58.
Uphaus T, Richards T, Weimar C, Neugebauer H, Poli S, Weissenborn K, Imray C, Michalski D, Rashid H, Loftus I, et al. Revacept, an inhibitor of platelet adhesion in symptomatic carotid stenosis: a multicenter randomized phase II trial. Stroke. 2022;53:2718–2729. doi: 10.1161/STROKEAHA.121.037006
59.
Mazighi M, Kohrmann M, Lemmens R, Lyrer PA, Molina CA, Richard S, Toni D, Plétan Y, Sari A, Meilhoc A, et al; ACTIMIS Study Group. Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial. Lancet Neurol. 2024;23:157–167. doi: 10.1016/S1474-4422(23)00427-1
60.
Mulorz J, Mazrekaj A, Sehl J, Arnautovic A, Garabet W, Krott KJ, Schelzig H, Elvers M, Wagenhäuser MU. Relative thrombus burden ratio reveals overproportioned intraluminal thrombus growth-potential implications for abdominal aortic aneurysm. J Clin Med. 2024;13:962. doi: 10.3390/jcm13040962
61.
Alshehri OM, Hughes CE, Montague S, Watson SK, Frampton J, Bender M, Watson SP. Fibrin activates GPVI in human and mouse platelets. Blood. 2015;126:1601–1608. doi: 10.1182/blood-2015-04-641654
62.
Gauer JS, Duval C, Xu RG, Macrae FL, McPherson HR, Tiede C, Tomlinson D, Watson SP, Ariëns RAS. Fibrin-glycoprotein VI interaction increases platelet procoagulant activity and impacts clot structure. J Thromb Haemost. 2023;21:667–681. doi: 10.1016/j.jtha.2022.09.004
Information & Authors
Information
Published In
Copyright
© 2024 American Heart Association, Inc.
Versions
You are viewing the most recent version of this article.
History
Received: 20 December 2023
Accepted: 14 August 2024
Published online: 29 August 2024
Published in print: November 2024
Keywords
Subjects
Authors
Disclosures
None.
Sources of Funding
This work was supported by Deutsche Forschungsgemeinschaft (German Research Foundation), Collaborative Research Centre TRR259 (Aortic Disease; grant No. 397484323: TP A07 to H. Schelzig and M. Elvers, TP B08 to M. Grandoch, and TP C03 to M.U. Wagenhäuser), and RTG 2816 (grant No. 464254052: to M. Chatterjee).
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
- Tracking GP VI in Abdominal Aortic Aneurysms: A Crucial Pathological Link?, Arteriosclerosis, Thrombosis, and Vascular Biology, 44, 11, (2318-2320), (2024)./doi/10.1161/ATVBAHA.124.321703
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to access the full text.
eLetters(0)
eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.
Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.